Kingsview Wealth Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$15.6M Sell
71,619
-211
-0.3% -$46.8K 0.21% 92
2025
Q4
$16.4M Buy
71,830
+883
+1% +$201K 0.24% 80
2025
Q3
$16.4M Buy
70,947
+824
+1% +$168K 0.25% 73
2025
Q2
$13M Buy
70,123
+1,434
+2% +$267K 0.22% 82
2025
Q1
$14.4M Buy
68,689
+87
+0.1% +$16.9K 0.27% 64
2024
Q4
$12.2M Sell
68,602
-5,499
-7% -$1.01M 0.24% 77
2024
Q3
$14.6M Buy
74,101
+2,272
+3% +$424K 0.31% 56
2024
Q2
$12.3M Buy
71,829
+9,185
+15% +$1.52M 0.29% 66
2024
Q1
$11.4M Sell
62,644
-39,894
-39% -$6.88M 0.29% 69
2023
Q4
$15.9M Sell
102,538
-2,101
-2% -$306K 0.47% 44
2023
Q3
$15.6M Buy
104,639
+28,071
+37% +$4.12M 0.56% 33
2023
Q2
$10.3M Sell
76,568
-4,962
-6% -$728K 0.4% 49
2023
Q1
$13M Sell
81,530
-6,931
-8% -$1.06M 0.55% 34
2022
Q4
$14.3M Sell
88,461
-5,783
-6% -$887K 0.62% 29
2022
Q3
$12.6M Sell
94,244
-2,682
-3% -$385K 0.6% 31
2022
Q2
$14.8M Buy
96,926
+14,898
+18% +$2.28M 0.71% 19
2022
Q1
$13.3M Buy
82,028
+3,517
+4% +$511K 0.59% 30
2021
Q4
$10.6M Buy
78,511
+1,201
+2% +$142K 0.44% 44
2021
Q3
$8.34M Buy
77,310
+10,145
+15% +$1.16M 0.4% 49
2021
Q2
$7.67M Buy
67,165
+17,952
+36% +$2.02M 0.38% 50
2021
Q1
$5.34M Buy
49,213
+5,660
+13% +$605K 0.3% 71
2020
Q4
$4.67M Buy
43,553
+4,843
+13% +$465K 0.34% 67
2020
Q3
$3.39M Buy
38,710
+6,363
+20% +$599K 0.3% 82
2020
Q2
$3.18M Buy
32,347
+4,758
+17% +$419K 0.32% 81
2020
Q1
$2.1M Buy
27,589
+10,260
+59% +$874K 0.28% 96
2019
Q4
$1.53M Buy
17,329
+7,242
+72% +$601K 0.19% 149
2019
Q3
$764K Sell
10,087
-6,684
-40% -$458K 0.12% 185
2019
Q2
$1.22M Sell
16,771
-2,527
-13% -$199K 0.2% 128
2019
Q1
$1.55M Sell
19,298
-24,342
-56% -$1.99M 0.24% 121
2018
Q4
$4.02M Buy
43,640
+580
+1% +$51K 0.88% 23
2018
Q3
$4.07M Buy
43,060
+868
+2% +$82.3K 0.83% 27
2018
Q2
$3.91M Sell
42,192
-454
-1% -$44.3K 0.93% 22
2018
Q1
$4.04M Buy
42,646
+36,201
+562% +$3.98M 1% 18
2017
Q4
$623K Sell
6,445
-22
-0.3% -$2.07K 0.22% 141
2017
Q3
$575K Buy
6,467
+2,241
+53% +$171K 0.25% 125
2017
Q2
$306K Buy
4,226
+581
+16% +$39.1K 0.16% 180
2017
Q1
$238K Buy
+3,645
New +$229K 0.14% 199

Other funds holding ABBV

Kingsview Wealth Management's ABBV Position: Q1 2026 in Review

Kingsview Wealth Management reduced its AbbVie (ABBV) stake by 0.29% in Q1 2026, selling an estimated $46.8K and leaving 71,619 shares worth $15.6M. The position accounts for 0.21% of the portfolio, ranked #92.

Kingsview Wealth Management first reported a position in ABBV in Q1 2017 and has held it in 37 quarters since. The position peaked at $16.4M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Kingsview Wealth Management held 71,619 shares of AbbVie worth $15.6M as of Q1 2026.
  • Kingsview Wealth Management sold 211 AbbVie shares in Q1 2026, an estimated $46.8K.
  • AbbVie made up 0.21% of Kingsview Wealth Management's portfolio in Q1 2026, its #92 holding.
  • Kingsview Wealth Management first reported a position in AbbVie in Q1 2017 and has held it in 37 quarters since.
  • Kingsview Wealth Management's AbbVie position peaked at $16.4M in Q3 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Kingsview Wealth Management's 13F filing for Q1 2026, filed 12 May 2026.